Summary of key studies evaluating the role of allogeneic HCT in Hodgkin lymphoma
| Study . | Type . | # of pts . | Prior AHSCT . | Donor type . | Conditioning . | PFS . | OS . |
|---|---|---|---|---|---|---|---|
| 42 | Retrospective registry (EBMT) | 168 | 52% | MSD 70%, MUD 30% | MAC 47%, RIC 53% | 20% MAC and 18% RIC at 5 y | 22% MAC and 28% RIC at 5 y |
| 43 | Single-center prospective | 58 | 83% | MSD 43%, MUD 57% | RIC 100% (fludarabine/ melphalan) | 32% at 2 y | 64% at 2 y |
| 44 | Retrospective registry (EBMT) | 285 | 80% | MSD 60%, MUD 33% | RIC/NMA 100% fludarabine based (79.5%), low-dose TBI (16%) | 25% at 3 y | 29% at 3 y |
| 45 | Retrospective registry (CIBMTR) | 143 | 89% | Unrelated 100% (matched in 77%) | RIC/NMA 100%, melphalan based 34% | 20% at 2 y | 37% at 2 y |
| 46 | Multicenter retrospective in France | 98 | 91% | Haplo 35%, MUD 28%, CB 37% | RIC/NMA 100% | 58% EFS at 3 y | 76% at 3 y Improved GRFS in Haplo |
| 47 | Retrospective registry (Japanese society for HCT) | 122 | 67% | MSD 39% MUD 17% | MAC 30%, RIC 62% | 31% | 66% at 3 y |
| 48 | Retrospective multicenter in Italy | 198 | 86% | MSD/MUD 67%, Haplo 33% | NMA 29%, RIC 51%, MAC 20% | Haplo 63%, MSD/MUD 29% at 2 y | 66% at 2 y |
| 12 | Retrospective registry (CIBMTR) | 596 | 80% | Haplo 24%, MSD 76% | NMA/RIC 100% | 34%-38% | 63% |
| 49 | Retrospective registry (EBMT) | 860 | MSD/MUD 64% Haplo 75% | 166 MSD/MUD, 694 Haplo | RIC 75%-80% | MSD/MUD 66%, Haplo 58% | MSD/MUD 82%, Haplo 70% Higher NRM in Haplo |
| Study . | Type . | # of pts . | Prior AHSCT . | Donor type . | Conditioning . | PFS . | OS . |
|---|---|---|---|---|---|---|---|
| 42 | Retrospective registry (EBMT) | 168 | 52% | MSD 70%, MUD 30% | MAC 47%, RIC 53% | 20% MAC and 18% RIC at 5 y | 22% MAC and 28% RIC at 5 y |
| 43 | Single-center prospective | 58 | 83% | MSD 43%, MUD 57% | RIC 100% (fludarabine/ melphalan) | 32% at 2 y | 64% at 2 y |
| 44 | Retrospective registry (EBMT) | 285 | 80% | MSD 60%, MUD 33% | RIC/NMA 100% fludarabine based (79.5%), low-dose TBI (16%) | 25% at 3 y | 29% at 3 y |
| 45 | Retrospective registry (CIBMTR) | 143 | 89% | Unrelated 100% (matched in 77%) | RIC/NMA 100%, melphalan based 34% | 20% at 2 y | 37% at 2 y |
| 46 | Multicenter retrospective in France | 98 | 91% | Haplo 35%, MUD 28%, CB 37% | RIC/NMA 100% | 58% EFS at 3 y | 76% at 3 y Improved GRFS in Haplo |
| 47 | Retrospective registry (Japanese society for HCT) | 122 | 67% | MSD 39% MUD 17% | MAC 30%, RIC 62% | 31% | 66% at 3 y |
| 48 | Retrospective multicenter in Italy | 198 | 86% | MSD/MUD 67%, Haplo 33% | NMA 29%, RIC 51%, MAC 20% | Haplo 63%, MSD/MUD 29% at 2 y | 66% at 2 y |
| 12 | Retrospective registry (CIBMTR) | 596 | 80% | Haplo 24%, MSD 76% | NMA/RIC 100% | 34%-38% | 63% |
| 49 | Retrospective registry (EBMT) | 860 | MSD/MUD 64% Haplo 75% | 166 MSD/MUD, 694 Haplo | RIC 75%-80% | MSD/MUD 66%, Haplo 58% | MSD/MUD 82%, Haplo 70% Higher NRM in Haplo |
AHSCT, autologous hematopoietic stem cell transplant; CB, cord blood; Haplo, haploidentical donor; GRFS, GVHD free and relapse free survival; MSD, matched sibling donor; MUD, matched unrelated donor; NMA, nonmyeloablative; TBI, total-body irradiation.